title: Is Human Kallikrein 11 in Non-small Cell Lung Cancer Treated Chemoradiotherapy Associated with Survival?
abstract: OBJECTIVE
  Involvement of human kallikreins (hKs) in human cancers has been reported and several hKs are promising biomarkers of various cancers. The aim of this study was to evaluate the prognostic significance of hK11 expression in patients with non-metastatic non-small cell lung cancer (NSCLC).
  
  
  METHODS
  The study included 44 patients with NSCLC. hK11 expression was determined by immunohistochemical staining.
  
  
  RESULTS
  The estimation of disease-free and overall survival by Kaplan-Meier was 11 months and 17 months, respectively. The estimation of overall survival by Kaplan-Meier was significantly higher in patients with hK11 strongly positive (2+) than in those with hK11 weakly positive (1+) (20 months vs. 11 months, p=0.032). Although not statistically different, the estimation of disease-free survival by Kaplan-Meier was higher in patients with hK11 strongly positive (2+) than in those with hK11 weakly positive (1+) (12 months vs. 9 months, p=0.113). Multivariate Cox regression analysis showed that the overall survival rates were significantly associated with response to chemoradiotherapy and the degree of staining with hK11.
  
  
  CONCLUSIONS
  The stronger hK11 expression in NSCLC appears to be associated with better survival rates. hK11 may be a prognostic biomarker of NSCLC.
authors.affiliation: Department of Radiation Oncology, Kayseri Education and Research Hospital, Kayseri, Turkey.
authors.forename: Dilek
authors.initials: D
authors.lastname: Unal
authors.affiliation: Department of Radiation Oncology, Erciyes University Medical Faculty, Kayseri, Turkey.
authors.forename: Celalettin
authors.initials: C
authors.lastname: Eroglu
authors.affiliation: Department of Pathology, Kayseri Education and Research Hospital, Kayseri, Turkey.
authors.forename: Arzu
authors.initials: A
authors.lastname: Tasdemir
authors.affiliation: Department of Pathology, Kayseri Education and Research Hospital, Kayseri, Turkey.
authors.forename: Hatice
authors.initials: H
authors.lastname: Karaman
authors.affiliation: Department of Radiation Oncology, Sutcu Imam University Medical Faculty, Kahramanmaras, Turkey.
authors.forename: Neslihan
authors.initials: N
authors.lastname: Kurtul
authors.affiliation: Department of Medical Oncology, Kayseri Education and Research Hospital, Kayseri, Turkey.
authors.forename: Arzu
authors.initials: A
authors.lastname: Oguz
authors.affiliation: Department of Medical Oncology, Kayseri Education and Research Hospital, Kayseri, Turkey.
authors.forename: Sema Sezgin
authors.initials: SS
authors.lastname: Goksu
authors.affiliation: Department of Radiation Oncology, Erciyes University Medical Faculty, Kayseri, Turkey.
authors.forename: Bunyamin
authors.initials: B
authors.lastname: Kaplan
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D006801:Humans; D007610:Kallikreins; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D009367:Neoplasm Staging; D011379:Prognosis; D012697:Serine Endopeptidases / Q000235:genetics*; D015996:Survival Rate
chemical_list: C114880:trypsin-like serine protease; D007610:Kallikreins; D012697:Serine Endopeptidases
keywords: Kallikrein-11; Lung neoplasms; Survival